ESR2 and ovarian carcinoma: They indicate that ER‐β inhibits NF‐κB via a non‐canonical interaction with its subunit p‐65 and that ER‐β increases the sensitivity of chemotherapy‐resistant epithelial ovarian cancer cell lines as shown in Figure 2 (Borella et al. 2023).